Updates in advanced prostate cancer 2018

被引：14
作者：
Armstrong, Andrew J. [1 ,2 ]
机构：
[1] Duke Univ, Duke Canc Inst, Div Med Oncol, DUMC Box 103861, Durham, NC 27710 USA
[2] Duke Univ, Duke Canc Inst, Div Urol, DUMC Box 103861, Durham, NC 27710 USA
来源：
PROSTATE CANCER AND PROSTATIC DISEASES | 2018年 / 21卷 / 04期
关键词：
RADIUM-223;
D O I：
10.1038/s41391-018-0100-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：449 / 450
页数：2
相关论文
共 11 条
[1]   Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study [J].
Aggarwal, Rahul ;
Huang, Jiaoti ;
Alumkal, Joshi J. ;
Zhang, Li ;
Feng, Felix Y. ;
Thomas, George V. ;
Weinstein, Alana S. ;
Friedl, Verena ;
Zhang, Can ;
Witte, Owen N. ;
Lloyd, Paul ;
Gleave, Martin ;
Evans, Christopher P. ;
Youngren, Jack ;
Beer, Tomasz M. ;
Rettig, Matthew ;
Wong, Christopher K. ;
True, Lawrence ;
Foye, Adam ;
Playdle, Denise ;
Ryan, Charles J. ;
Lara, Primo ;
Chi, Kim N. ;
Uzunangelov, Vlado ;
Sokolov, Artem ;
Newton, Yulia ;
Beltran, Himisha ;
Demichelis, Francesca ;
Rubin, Mark A. ;
Stuart, Joshua M. ;
Small, Eric J. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (24) :2492-+
[2]   Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies [J].
Alpajaro, Sigfred Ian R. ;
Harris, Jerad A. K. ;
Evans, Christopher P. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2019, 22 (01) :16-23
[3]   Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer? [J].
Brown, Landon C. ;
Sonpavde, Guru ;
Armstrong, Andrew J. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (03) :419-430
[4]   Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis [J].
Calopedos, R. J. S. ;
Chalasani, V. ;
Asher, R. ;
Emmett, L. ;
Woo, H. H. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (03) :352-360
[5]   Platinum sensitivity in metastatic prostate cancer: does histology matter? [J].
Humeniuk, Michael S. ;
Gupta, Rajan T. ;
Healy, Patrick ;
McNamara, Megan ;
Ramalingam, Sundhar ;
Harrison, Michael ;
George, Daniel ;
Zhang, Tian ;
Wu, Yuan ;
Armstrong, Andrew J. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (01) :92-99
[6]   Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database [J].
Keizman, D. ;
Fosboel, M. O. ;
Reichegger, H. ;
Peer, A. ;
Rosenbaum, E. ;
Desax, M-C ;
Neiman, V. ;
Petersen, P. M. ;
Mueller, J. ;
Cathomas, R. ;
Gottfried, M. ;
Dresler, H. ;
Sarid, D. ;
Mermershtain, W. ;
Rouvinov, K. ;
Mortensen, J. ;
Gillessen, S. ;
Daugaard, G. ;
Omlin, A. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (03) :289-293
[7]   The use of PET/CT in prostate cancer [J].
Li, Roger ;
Ravizzini, Gregory C. ;
Gorin, Michael A. ;
Maurer, Tobias ;
Eiber, Matthias ;
Cooperberg, Matthew R. ;
Alemozzaffar, Mehrdad ;
Tollefson, Matthew K. ;
Delacroix, Scott E. ;
Chapin, Brian F. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (01) :4-21
[8]   p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer [J].
Maughan, Benjamin L. ;
Guedes, Liana B. ;
Boucher, Kenneth ;
Rajoria, Gaurav ;
Liu, Zach ;
Klimek, Szczepan ;
Zoino, Roberto ;
Antonarakis, Emmanuel S. ;
Lotan, Tamara L. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (02) :260-268
[9]   Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study [J].
Ng, Huah Shin ;
Koczwara, Bogda ;
Roder, David ;
Vitry, Agnes .
PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (03) :403-410
[10]   Current approaches to incorporation of radium-223 in clinical practice [J].
Parker, Chris ;
Heidenreich, Axel ;
Nilsson, Sten ;
Shore, Neal .
PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (01) :37-47
12